Scholars Central

Conference abstractPublished 20 Nov 2013

The rationale for dual targeting MET and EGFR in non-small cell lung cancer

Authors: Yu-Wen Zhang

Van Andel Research Institute, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancer, which is the leading cause of death among all human cancers. Receptor tyrosine kinases (RTKs) play important roles in NSCLC development and progression, and are attractive targets for cancer intervention. Both MET and EGFR are RTKs that are frequently activated in NSCLC either by overexpression, amplification or mutation. EGFR-targeted therapies (erlotinib and gefitinib) have been used for treating advanced lung cancer patients; however such treatments primarily benefit patients who carry sensitive EGFR mutations, leaving the majority of patients refractory to EGFR-targeted therapy. MET is often co-expressed with EGFR, and MET amplification is also one of the resistance mechanisms for escaping EGFR-targeted therapy. We reasoned that MET and EGFR cooperate in driving NSCLC development and progression, and MET inhibition would sensitize cancer cells lacking EGFR mutations to EGFR-targeted therapy. Using both in vitro cell-based assays and in vivo preclinical xenograft model systems, we demonstrated that combined inhibition of MET and EGFR significantly strengthened anti-cancer effects against NSCLC tumors in cellular context-dependent manners: enhancing suppression of proliferation with or without inducing apoptosis, and/or preventing a resistant mechanism that mutually bypasses individual inhibitor treatment. These data provide mechanistic understanding of how combination therapies targeting both MET and EGFR improves efficacy and reveal a potentially effective treatment regimen for NSCLC patients who lack EGFR mutations.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Yu-Wen Zhang”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels